Effects of the tumor vasculature targeting agent NGR-TNF on the tumor microenvironment in murine lymphomas.
- Published in:
- Investigational New Drugs, 2006, v. 24, n. 1, p. 27, doi. 10.1007/s10637-005-4540-2
- By:
- Publication type:
- Article
Works matching IS 01676997 AND DT 2006 AND VI 24 AND IP 1
Results: 7
1
2
Phase II trial of imatinib (Gleevec®) in patients with metastatic renal cell carcinoma.
- Published in:
- Investigational New Drugs, 2006, v. 24, n. 1, p. 85, doi. 10.1007/s10637-005-4543-z
- By:
- Publication type:
- Article
3
Phase I clinical trial of weekly docetaxel and exisulind, a novel inducer of apoptosis.
- Published in:
- Investigational New Drugs, 2006, v. 24, n. 1, p. 79, doi. 10.1007/s10637-005-4542-0
- By:
- Publication type:
- Article
4
In vitro characterization of the human biotransformation and CYP reaction phenotype of ET-743 (Yondelis®, Trabectidin®), a novel marine anti-cancer drug.
- Published in:
- Investigational New Drugs, 2006, v. 24, n. 1, p. 3, doi. 10.1007/s10637-005-4538-9
- By:
- Publication type:
- Article
5
The combination of sulfinosine and 8-Cl-cAMP induces synergistic cell growth inhibition of the human neuroblastoma cell line in vitro.
- Published in:
- Investigational New Drugs, 2006, v. 24, n. 1, p. 15, doi. 10.1007/s10637-005-4539-8
- By:
- Publication type:
- Article
6
From methotrexate to pemetrexed and beyond. A review of the pharmacodynamic and clinical properties of antifolates.
- Published in:
- Investigational New Drugs, 2006, v. 24, n. 1, p. 37, doi. 10.1007/s10637-005-4541-1
- By:
- Publication type:
- Article
7
A phase II open-label trial of apomine (SR-45023A) in patients with refractory melanoma.
- Published in:
- Investigational New Drugs, 2006, v. 24, n. 1, p. 89, doi. 10.1007/s10637-005-4544-y
- By:
- Publication type:
- Article